Entitäten © Block/Kösters Version 2.0 – 2014-01-20 119/125 AML-GO A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED /
{"Image DocumentName": "AML-GO Kohorte 1 (mindestens 54 Patienten)", "Image ImageDescription": "A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN. RELAPSED / REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED / REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) Einschlusskriterien. Patients with documented relapsed or refractory AML, except acute promyelocytic leukemia (APL [M3 subtype]), or relapsed or refractory high-risk MDS (high-risk MDS defined as IPSS Int-2 or high and\u00b3 10% blasts in bone marrow) Age >= 18 years. Ausschlusskriterien. Prior treatment with a Hh pathway inhibitor. Patients with current evidence of active CNS leukemia. Patients with any other active malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). Prior therapy for the treatment of malignancy within 14 days of Day 1, with the exception of: Hydroxyurea in patients who need to continue this agent to maintain WBC counts <= 50,000/mL. Hydroxyurea must be discontinued by Day 14 of the study. Kohorte 1 (mindestens 54 Patienten) Patienten bekommen 1 Kapsel Vismodegib (150 mg) pro Tag bis zum Progress der Erkrankung. Beginn Ende offen. Ansprechpartner UKE: PI Prof. Walter Fiedler SI Dr. Maxim Kebenko et al SK Petra K\u00fchne \u00a9 Block/K\u00f6sters. Version 2.0 \u2013", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}